This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Novartis Reports Additional Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.
Novartis (NVS) Announces Data on Asthma Drugs & Kisqali
by Zacks Equity Research
Novartis (NVS) announces data from late-stage studies on asthma drugs and breast cancer drug, Kisqali.
Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for Rituxan to treat children with two rare blood vessel disorders. The company also extends the offer period to acquire Spark Therapeutics.
AbbVie (ABBV) Gets FDA Nod for Label Expansion of HCV Drug
by Zacks Equity Research
AbbVie (ABBV) gets FDA approval for the label expansion of Mavyret.
Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance
by Zacks Equity Research
Incyte (INCY) outperforms the industry on strong performance of Jakafi and encouraging pipeline progress.
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late
by Zacks Equity Research
Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Here's Why AstraZeneca (AZN) is Outperforming Its Industry
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN
by Zacks Equity Research
Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.
Incyte Treats First Patient in Phase III Vitiligo Study
by Zacks Equity Research
Incyte (INCY) treats first patient in the TRuE-V clinical program on the cream formulation of ruxolitinib for the treatment of vitiligo.
Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy
by Zacks Equity Research
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Novo Nordisk's Semaglutide in Tablet Form Gets FDA Approval
by Zacks Equity Research
Novo Nordisk's (NVO) semaglutide in tablet form gets FDA nod as an adjunct to diet and exercise to improve glycaemic control in adults with type II diabetes mellitus.
Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
by Kinjel Shah
FDA approves label expansion of Merck's (MRK) Keytruda and J&J's (JNJ) Erleada.
Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
by Zacks Equity Research
Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.
Novartis Announces New Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces new positive data from a phase III study on Cosentyx in patients with active nr-axSpA.
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
by Zacks Equity Research
J&J's (JNJ) sBLA seeking approval for Tremfya for active psoriatic arthritis is based on data from the phase III DISCOVER 1 and 2 studies.
Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
by Zacks Equity Research
Alder (ALDR) signs an agreement to be acquired by Danish pharmaceutical company, Lundbeck A/S, for $1.95 billion.
Is Novartis (NVS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Biogen Stops Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
by Kinjel Shah
The FDA approves new warnings about inflammation risk to be added to labels of Pfizer's (PFE) Ibrance, Eli Lilly's (LLY) Verzenio and Novartis' (NVS) Kisqali.
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
by Zacks Equity Research
Adverum Biotechnologies (ADVM) announces data from one cohort of an early-stage study, evaluating its gene therapy candidate, ADVM-022, in patients with wet AMD.
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
by Zacks Equity Research
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (NVS) Outperforming Other Medical Stocks This Year?
4 Big Drugmakers Boasting Impressive Oncology Pipelines
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe
by Zacks Equity Research
The FDA is expected to give its decision on Allergan's (AGN) BLA for its anti-VEGF product, abicipar pegol in mid-2020, while the EMA's decision is expected in the second half of 2020.